Modern Aesthetic Solutions will be presenting the EVRF device at the Vacular Society AGM from 28th to 30th November 2012.
Dr Attila Szabó MD, PhD of the Semmelweis University Budapest, Hungary has recently completed a trial using the EVRF.
Between July 2011 and September 2012 he treated 150 patients, recording 149 of those as having witnessed total occlusion of the Saphenous Vein. He concluded that the EVRF saphenous ablation is a safe, painless procedure for the treatment of the reflux of the GSV and/or SSV with high patient acceptance and minimal postoperative discomfort allows the quick return to work and normal life.
Dr Lars Rasmussen, Denmark, following a recent study comparing all endovenous procedures, has reported that “EVRF is one of the thermo-ablation methods with the lowest pain score”.
EVRF is now being offered by Mr Paul Burke at Barringtons Private Hospital, Limerick, Eire.
Daily Mail Reporter, Angela Epstein, compares different options for varicose vein treatment but the report concludes that most have their uses and good practice is to be able to offer a variety of techniques. She comments on the use of Radio Frequency, the basis of the EVRF device,
“With local anaesthetic, a thin catheter is inserted into the vein, then radiofrequency current is used to collapse the vein walls. The technique, called radio-frequency ablation, is very similar to laser in terms of application, though not as successful. Stockings usually need to be worn for ten to 14 days, as these hold the vein area in place, making it more comfortable for the patient”.
ADVANTAGES: This targets the vein more accurately than laser treatment, says Mr Scurr. This means less chance of burning the tissues around the vein and so less risk of scarring and nerve damage, and slightly less pain. It’s good for early varicose veins rather than bulging ones on the lower part of the leg.
DISADVANTAGES: Slightly higher failure rate than endovenous laser ablation but still more than 90 per cent successful, says Mr Chaloner.
We are soon to be introducing a new proprietary needle specifically designed to treat the blue mid-sized multi-directional veins on the legs where several veins seem to merge superficially giving an unsightly, often raised, appearance. These are usually the recidivism from previous sclerotherapy treatments. If successful, these may avoid the use of foam sclerotherapy in the future. We hope to have clinical evidence available by October 2012.
Mr Paul Burke, Consultant Surgeon at St. Johns Hospital, Limmerick, is now offering the EVRF treatment to his patients. He tells us that with the ease of use and lack of concerns associated with the laser alternatives, coupled with the significant cost savings achieved in comparison to similar treatments, the EVRF seemingly provides a perfect solution.
We are delighted to announce that Spire Hospitals are offering the EVRF treatment from their Manchester and Regency hospitals. Under the direction of Mr Ferdinand Serracino-Inglott, Consultant Surgeon, saphenous treatments using EVRF are being performed with great success.
Today we presented the EVRF at the Charing Cross Symposium at Imperial College, London, to great applause. In conjunction with FCare Systems, its manufacturer, we welcomed the enthusiam shown by so many in the vascular field and we look forward to attending their clinics in due course so that we can show them the extent of treatment which EVRF offers, coupled with its proven efficacy.
Researchers have identified the culprit behind the varicose veins.
Dr. Thomas Korff and his group at the Division of Cardiovascular Physiology of Heidelberg University’s Institute of Physiology and Pathophysiology have shown that the pathological remodeling processes causing varicose veins are mediated by a single protein.
As a response to increased stretching of the vessel wall, this protein triggers the production of several molecules promoting changes in wall architecture. The paper published in the current issue of FASEB Journal may offer a possibility for using drugs to decelerate the formation of or even prevent new varicose veins.
Previously, no suitable experimental systems existed for studying the way in which these changes in the cells of the blood vessels are controlled. For their studies, Korff and his team took advantage of the fact that blood vessels in the mouse ear are clearly visible and are also easily accessible for minor surgical procedures. In order to artificially set off processes that are similar to the formation of varicose veins, they tied off a vein with a thin thread. The elevated pressure in the vessels caused by the pooled blood led to the recognizable remodeling characteristic of varicose veins. In addition, in the affected veins, the cell proliferation rate and the production of MMP-2 increased.
MMP-2 is an enzyme that breaks down the non-cellular components of the connective tissue of the blood vessels. On the other hand, there were no signs of an inflammatory response, which can be observed during other vessel remodeling processes. “Nevertheless, the cellular mechanisms that control the formation of varicose veins appear to be similar to mechanisms that orchestrate the remodeling of arteries in patients with high blood pressure,” Korff explains. The transcription factor AP-1 which regulates the activity of certain genes and thus the corresponding protein production is regulated by the filling pressure in the blood vessels and in turn controls the formation of varicose veins, Korff adds.
If AP-1 is inhibited, thus prohibiting it from activating genes, the characteristic corkscrew-like varicose veins do not form and cell proliferation and the production of enzymes that break down connective tissue remain at normal levels. In a further experiment, the group showed that the results obtained in the mouse are also valid for humans. Varicose veins that have been surgically removed from patients exhibited the same cellular and molecular changes as the varicose veins created artificially in the mouse ear.
Based on these results, Korff plans more studies. “Using our model, we can now more precisely analyze the early stages of the disorder and test possible drugs for their ability to prevent varicose vein formation, which, as a result, may improve the quality of life of afflicted patients.” According to the German Vascular League, 30 million people suffer from minor vein-related symptoms, whereby women are affected around twice as often as men. According to a health report published by the German government, 15 to 20 percent of the population has varicose veins. Source-Eurekalert
UK Head Office
The Hub @ Elstree Aerodrome
Hogg Lane, Elstree, Herts WD6 3AW
Telephone: +44 (0) 844 884 9966
Facsimile: +44 (0) 871 433 4479
12555 Biscayne Blvd
United States of America
MIDDLE EAST SALES OFFICE